Zoetis Inc (ZTS) Receives Consensus Rating of “Buy” from Brokerages

Zoetis Inc (NYSE:ZTS) has received an average rating of “Buy” from the twenty research firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $73.72.

A number of research analysts have recently commented on the stock. BMO Capital Markets set a $78.00 price target on shares of Zoetis and gave the company a “hold” rating in a research report on Monday, January 22nd. Piper Jaffray Companies restated a “buy” rating and set a $86.00 price target on shares of Zoetis in a research report on Thursday, January 18th. Jefferies Group restated a “buy” rating and set a $89.00 price target on shares of Zoetis in a research report on Tuesday, January 16th. Zacks Investment Research downgraded shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price objective for the company. in a report on Saturday, January 13th. Finally, Cantor Fitzgerald set a $85.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a report on Thursday, January 11th.

Several large investors have recently modified their holdings of ZTS. Shelton Capital Management bought a new position in shares of Zoetis during the second quarter valued at about $232,000. Arrowstreet Capital Limited Partnership bought a new position in shares of Zoetis during the second quarter valued at about $917,000. Raymond James Financial Services Advisors Inc. raised its stake in shares of Zoetis by 51.4% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 31,041 shares of the company’s stock valued at $1,936,000 after acquiring an additional 10,539 shares during the last quarter. Public Employees Retirement System of Ohio raised its stake in shares of Zoetis by 3.9% during the second quarter. Public Employees Retirement System of Ohio now owns 237,680 shares of the company’s stock valued at $14,826,000 after acquiring an additional 9,028 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd increased its position in shares of Zoetis by 7.3% during the second quarter. Dynamic Technology Lab Private Ltd now owns 5,901 shares of the company’s stock valued at $368,000 after buying an additional 401 shares during the period. 93.72% of the stock is owned by hedge funds and other institutional investors.

Zoetis (ZTS) traded up $1.12 on Wednesday, hitting $74.36. 2,102,478 shares of the stock were exchanged, compared to its average volume of 2,920,167. The stock has a market cap of $36,080.00, a price-to-earnings ratio of 39.14, a P/E/G ratio of 1.61 and a beta of 1.07. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. Zoetis has a 12-month low of $52.00 and a 12-month high of $80.13.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, January 19th will be paid a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a dividend yield of 0.68%. This is an increase from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date of this dividend is Thursday, January 18th. Zoetis’s dividend payout ratio is 26.32%.

TRADEMARK VIOLATION NOTICE: This report was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2018/02/14/zoetis-inc-zts-receives-consensus-rating-of-buy-from-brokerages.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply